Chen Debora Ml, Han Silvia, Summers Allison, Wang Jingyun, Rice Melissa, Mallios Jenelle, Leslie Louis, Harb Elise N, Qureshi Riaz
Herbert Wertheim School of Optometry and Vision Science, UC Berkeley, Berkeley, CA, USA.
Southern California College of Optometry, Marshall B. Ketchum University, Fullerton, CA, USA.
Cochrane Database Syst Rev. 2025 Jul 2;7(7):CD015820. doi: 10.1002/14651858.CD015820.pub2.
Amblyopia is a neurodevelopmental visual disorder that can be successfully treated, particularly in younger children. However, the effectiveness of treatment is often limited by adherence. This review discusses the efficacy and harms of interventions designed to increase adherence to amblyopia treatments in children.
To assess the efficacy and harms of various behavioral interventions for improving children's objective adherence to amblyopia treatments.
We searched CENTRAL, MEDLINE, Embase.com, LILACS, ClinicalTrials.gov, and ICTRP. We did not use any date or language restrictions in the electronic searches for trials. The latest search date was 24 May 2024. We also searched the bibliographies of the included trials and any relevant systematic reviews.
We included randomized controlled trials (RCTs) and quasi-RCTs in children aged three to 18 years old at the start of the trial. We included participants with bilateral or unilateral amblyopia, comparing interventions to improve treatment adherence. Interventions were categorized as behavioral (e.g. rewards, informational videos), digital (e.g. video games), and different approaches to patching (e.g. different types of patches). We excluded participants with deprivation amblyopia or with a history of ocular diseases, unrelated to amblyopia, that could affect visual acuity (VA).
Our critical outcome was adherence to treatment using objective adherence measures from one week up to three months. 'Adherence' was defined as the percentage of hours of actual treatment undertaken by the participant compared with the hours of prescribed treatment. Our important outcomes were measured at two time intervals, one week to three months and four to six months: 1. Adherence to prescribed treatment using subjective measures 2. Total hours of adherence 3. Change in recognition VA in the amblyopic eye from baseline 4. Change in random dot stereoacuity We also assessed harms, such as adverse effects and the burden of adherence monitoring, in studies that reported them by the end of the study.
We used the Cochrane risk of bias (RoB 2) tools for parallel and cross-over trials to assess the risk of bias in the included studies.
We synthesized results for each outcome using meta-analyses of mean differences (MD), when data were available, using fixed-effect inverse variance models when fewer than three studies were available and random-effects models if three or more studies were available. Where this was not possible due to the nature of the data, we synthesized the results qualitatively. We used GRADE to assess the certainty of the evidence for prespecified outcomes that were reported.
We included a total of 18 studies with 1456 total participants. Eleven studies reported the age of the participants, with mean ages between 4.1 and 6.2 years. Most studies enrolled children with anisometropic, strabismic, and mixed mechanism amblyopia. Four studies reported race and ethnicity, with three of those enrolling predominantly White participants, and one approximately half White and half Other.
Behavioral interventions Nine studies compared a single or combination of behavioral interventions to the standard of care or no intervention to improve adherence. Success in improving adherence varied across time frames, with no discernible pattern favoring the use of either a single or a combination of behavioral interventions, or whether the intervention was targeted at children or their caregivers. A majority of studies had a high risk of bias due to missing outcome data or some concerns about the risk of bias due to the described analyses. In general, there was little to no improvement in the change in logMAR VA or random dot stereoacuity at any time point. Digital stimulus interventions Six studies compared digital to non-digital stimulus interventions, with adherence reported as the same or worse with the digital intervention. No study extended past three months. Only one of the five studies evaluating change in logMAR VA reported significant improvement in three months. There was a high risk of bias due to missing outcome data. Only one out of four studies reported improvement in random dot stereoacuity. Different approaches to patching Three studies evaluated different approaches to patching. No study found evidence of change in adherence, VA, or stereoacuity at any time point. Harms No study reported any serious harm from interventions to improve adherence or from the treatment itself (e.g. patching). Non-serious harms included discomfort from occlusion dose monitors; patching expense, rash/itching, inability to tolerate the patch, and negative impact on activities of daily living; reverse or worsening of amblyopia from either patching or digital intervention; and double vision. Limitations of the evidence Studies were mainly excluded due to ineligible comparisons, interventions, or study designs. Several factors reduced data quality and downgraded the evidence certainty, including lack of objective measures of adherence, data heterogeneity, small sample size, imprecision, and non-reporting. Generalizability was limited by participant demographics. Few studies addressed equity-related factors and, when they did, the findings lacked standardization.
AUTHORS' CONCLUSIONS: Based on our review, the available data were of very low certainty. We were unable to draw conclusions about any differences in adherence, measured objectively, to amblyopia treatments in children using behavioral, digital interventions, or different approaches to patching compared to those receiving no intervention or standard of care. Similarly, we were unable to draw conclusions about any differences in improvement in logMAR VA and stereoacuity arising from these interventions. No data were available for any serious harms, but some data relating to non-serious harms were mentioned.
This Cochrane review had no dedicated funding.
Protocol: doi.org/10.1002/14651858.CD015820.
弱视是一种神经发育性视觉障碍,尤其在年幼儿童中可得到成功治疗。然而,治疗效果常常受到依从性的限制。本综述讨论旨在提高儿童弱视治疗依从性的干预措施的疗效和危害。
评估各种行为干预措施对提高儿童弱视治疗客观依从性的疗效和危害。
我们检索了Cochrane系统评价数据库、医学期刊数据库、Embase.com、拉丁美洲和加勒比卫生科学数据库、临床试验注册库以及国际临床试验注册平台。在电子检索试验时,我们未使用任何日期或语言限制。最新检索日期为2024年5月24日。我们还检索了纳入试验的参考文献以及任何相关的系统评价。
我们纳入了试验开始时年龄在3至18岁儿童的随机对照试验(RCT)和半随机对照试验。纳入双侧或单侧弱视的参与者,比较旨在提高治疗依从性的干预措施。干预措施分为行为干预(如奖励、信息视频)、数字干预(如电子游戏)以及不同的遮盖方法(如不同类型的眼罩)。我们排除了患有剥夺性弱视或有与弱视无关的眼部疾病史且可能影响视力(VA)的参与者。
我们的关键结局指标是使用从一周到三个月的客观依从性测量方法来评估治疗依从性。“依从性”定义为参与者实际接受治疗的小时数与规定治疗小时数的百分比。我们的重要结局指标在两个时间间隔进行测量,即一周至三个月和四个至六个月:1. 使用主观测量方法评估的规定治疗依从性;2. 总依从小时数;3. 弱视眼识别视力相对于基线的变化;4. 随机点立体视锐度的变化。我们还在研究结束时报告了危害的研究中评估了危害,如不良反应和依从性监测负担。
我们使用Cochrane偏倚风险(RoB 2)工具对平行试验和交叉试验评估纳入研究中的偏倚风险。
当有数据时,我们使用均数差(MD)的Meta分析对每个结局指标的结果进行综合,当研究少于三项时使用固定效应逆方差模型,若有三项或更多研究则使用随机效应模型。由于数据性质无法进行Meta分析时,我们对结果进行定性综合。我们使用GRADE评估报告的预定义结局指标证据的确定性。
我们共纳入18项研究,总计1456名参与者。11项研究报告了参与者的年龄,平均年龄在4.1至6.2岁之间。大多数研究纳入了屈光参差性、斜视性和混合机制性弱视的儿童。4项研究报告了种族和民族,其中3项主要纳入白人参与者,1项约一半为白人,一半为其他种族。
行为干预 9项研究比较了单一或联合行为干预与标准治疗或无干预措施以提高依从性。在不同时间框架内,提高依从性的成功率各不相同,没有明显的模式表明单一或联合行为干预更有利,也没有表明干预是针对儿童还是其照顾者更有利。由于结局数据缺失或对所描述分析的偏倚风险存在一些担忧,大多数研究存在较高的偏倚风险。总体而言,在任何时间点,logMAR视力或随机点立体视锐度的变化几乎没有改善。数字刺激干预 6项研究比较了数字刺激干预与非数字刺激干预,报告显示数字干预的依从性相同或更差。没有研究超过三个月。在评估logMAR视力变化的五项研究中,只有一项报告在三个月时有显著改善。由于结局数据缺失,存在较高的偏倚风险。四项研究中只有一项报告随机点立体视锐度有所改善。不同的遮盖方法 三项研究评估了不同的遮盖方法。没有研究发现任何时间点依从性、视力或立体视锐度有变化的证据。危害 没有研究报告提高依从性的干预措施或治疗本身(如遮盖)造成任何严重危害。非严重危害包括遮盖剂量监测器引起的不适;遮盖费用、皮疹/瘙痒、无法耐受眼罩以及对日常生活活动的负面影响;遮盖或数字干预导致弱视逆转或加重;以及复视。证据的局限性 研究主要因不适当的比较、干预措施或研究设计而被排除。几个因素降低了数据质量并降低了证据的确定性,包括缺乏依从性的客观测量、数据异质性、样本量小、不精确性以及未报告。可推广性受到参与者人口统计学特征的限制。很少有研究涉及与公平性相关的因素,即使涉及,结果也缺乏标准化。
基于我们的综述,现有数据的确定性非常低。我们无法得出关于使用行为、数字干预或不同遮盖方法的儿童与未接受干预或标准治疗的儿童相比,在客观测量的弱视治疗依从性方面存在任何差异的结论。同样,我们无法得出关于这些干预措施在logMAR视力和立体视锐度改善方面存在任何差异的结论。没有关于任何严重危害的数据,但提到了一些与非严重危害相关的数据。
本Cochrane综述没有专项资金。
方案:doi.org/https://doi.org/10.1002/14651858.CD015820 。 10.1002/14651858.CD015820 。